VA
TEVA icon

Vident Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Vident Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
54,886
+5,142
+10% +$171K 0.01% 719
2026
Q1 		$1.5M Sell
49,744
-732
-1% -$23.6K 0.01% 715
2025
Q4 		$1.58M Sell
50,476
-5,184
-9% -$128K 0.01% 650
2025
Q3 		$1.12M Buy
55,660
+15,935
+40% +$280K 0.01% 773
2025
Q2 		$666K Sell
39,725
-3,630
-8% -$58.6K 0.01% 901
2025
Q1 		$666K Buy
43,355
+195
+0.5% +$3.48K 0.01% 883
2024
Q4 		$951K Sell
43,160
-2,327
-5% -$42.3K 0.02% 658
2024
Q3 		$820K Sell
45,487
-1,070
-2% -$18.7K 0.02% 704
2024
Q2 		$757K Buy
+46,557
New +$717K 0.02% 699
2024
Q1 		– Sell
-40,732
Closed -$425K – 1421
2023
Q4 		$425K Buy
40,732
+11,580
+40% +$108K 0.01% 848
2023
Q3 		$297K Buy
+29,152
New +$271K 0.01% 909

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Vident Advisory's TEVA Position: Q2 2026 in Review

Vident Advisory increased its Teva Pharmaceuticals (TEVA) stake by 10% in Q2 2026, buying an estimated $171K and bringing the position to 54,886 shares worth $1.86M. The position accounts for 0.01% of the portfolio, ranked #719.

Vident Advisory first reported a position in TEVA in Q3 2023 and has held it in 11 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Vident Advisory held 54,886 shares of Teva Pharmaceuticals worth $1.86M as of Q2 2026.
  • Vident Advisory bought 5,142 Teva Pharmaceuticals shares in Q2 2026, an estimated $171K.
  • Teva Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #719 holding.
  • Vident Advisory first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.